Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma emission refers to the process by which an unstable atomic nucleus releases excess energy in the form of high-energy electromagnetic photons known as gamma rays. This typically occurs after alpha or beta decay leaves the nucleus in an excited state. Unlike alpha and beta particles, which are actual subatomic particles ejected from the nucleus, gamma emissions involve only energy release without changing the number of protons or neutrons in the atom. Gamma rays are highly penetrating ionizing radiation capable of passing through most materials—including human tissue—and pose significant health risks due to their ability to cause cellular and genetic damage[1][5][8][10]. While they play important roles in medical imaging and cancer therapy when controlled sources are used[9], uncontrolled exposure presents serious safety concerns.
Not applicable; however, some therapies use sources that emit gamma rays for their effects (e.g., radiotherapy uses isotopes emitting gamma radiation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on gamma emission.